TriSalus Life Sciences enters Thursday's aftermath carrying a guidance cut, a target-price trim, and short interest at a six-week high — all in the same 48-hour window.
The trigger was Tuesday's Q1 print. Revenue came in at $8.9M, missing the $10.4M consensus. EPS of $0.03 beat the $(0.16) estimate — an unusual combination of a top-line miss and a bottom-line beat. More damaging was the full-year revenue guidance: management slashed the FY2026 range from $60M–$62M to $54M–$57M, well below the $59.96M Street estimate. The stock closed Tuesday at $4.56, down a fraction on the week but up 8% on the month, suggesting the guidance cut landed into a market that had already partially de-risked.
Short positioning built visibly into the print. Short interest as a percentage of the free float rose from roughly 2.5% to 2.85% over the past week — a 13% jump in borrowed shares within five sessions. That move was the steepest weekly climb in the past 30 days and lifted SI to its highest level of the past six weeks. Borrow costs ticked up in parallel, with cost to borrow jumping 18% week-on-week to 1.05%. That is still a low absolute rate, and borrow availability remains ample, so there is no squeeze dynamic in the lending market. The ORTEX short score has crept to 52.6 — having risen every session this week — but remains in mid-range territory. Positioning looks cautious rather than aggressive.
The Street has maintained a constructive posture, but the target prices tell a narrower story. Lake Street — fresh today, May 13 — cut its target from $10 to $8 while holding a Buy rating. Canaccord has sat at $7 since March, having slashed from $12 to $7 in early 2026. The mean target is $8.80, nearly double the current price of $4.56. That gap is real, not a data artefact — the consensus reflects genuine belief in the platform, not stale entries. But the direction of revisions has been consistently downward since late 2025, and the guidance cut provides fresh ammunition for further trims. Factor scores offer limited comfort: EPS momentum ranks in the 26th percentile on a 30-day basis and the 22nd percentile on 90 days, while the EPS surprise score of 87 reflects the beat-on-the-bottom-line story — a discrepancy that the Street has historically found hard to price cleanly in med-tech names.
One institutional move worth noting: BlackRock added 746,000 shares as of the April 30 filing, nearly doubling its stake, while Wasatch Advisors initiated a 1.44M-share position in Q1. Those are meaningful signals from passive and active buyers at a time when insider activity has been tilted the other way — multiple C-suite executives, including President/CEO Mary Szela, made modest stock sales in March at prices around $3.85–$4.13, well below the current level. The insider sales were small in absolute dollar terms and concentrated in mid-March, suggesting routine tax or compensation-plan liquidations rather than a directional call.
The next event listed is May 14 — a follow-on earnings call or analyst call based on the event data — which means the market has not yet fully digested Tuesday's print. The key question going forward is less about whether the technology works (the PREDICTT trial enrolment announcement and the published pressure-enabled drug delivery study both speak to clinical momentum) and more about whether the revenue ramp can credibly resume after a guidance corridor that now sits 8–12% below prior expectations.
See the live data behind this article on ORTEX.
Open TLSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
